Reading BDTX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BDTX free→Reading BDTX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BDTX free→QuarterlyIQ Insights · BDTX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. On May 21, 2026, the Company announced results from its Phase 2 trial of silevertinib in frontline (“1L”) non-small cell lung cancer (“NSCLC”) patients with epidermal growth factor receptor (“EGFR”) non-classical mutations (“NCMs”). Silevertinib 1L NSCLC Phase 2 Results Summary Forty-three frontline NSCLC patients harboring a broad spectrum of EGFR-NCMs, including compound and P-Loop and C-Helix Compressing (“PACC”) mutations, were enrolled, including 19 patients with brain meta…
Results of Operations and Financial Condition. On May 7, 2026, Black Diamond Therapeutics, Inc. announced its financial results for the three months ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”…
Results of Operations and Financial Condition. On March 16, 2026, Black Diamond Therapeutics, Inc. announced its financial results for the year and three months ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the…
Other Events. On December 3, 2025, the Company announced topline data from its Phase 2 trial of silevertinib in 1L NSCLC patients with non-classical epidermal growth factor receptor (“EGFR”) mutations and outlined plans for a randomized Phase 2 trial of silevertinib in patients with newly diagnosed GBM. Silevertinib Phase 2 1L NSCLC Initial Clinical Results and Program Update 43 frontline NSCLC patients harboring a broad spectrum of 35 distinct non-classical EGFR mutations were enrolled, incl…
Results of Operations and Financial Condition. On December 3, 2025, Black Diamond Therapeutics, Inc. (the “Company”) issued a press release titled “Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM” and posted an updated corporate presentation to its website at https://investors.blackdiamondtherapeutics.com/events-presentations, which press release and presentation included updated financial guidance…
Results of Operations and Financial Condition. On November 6, 2025, Black Diamond Therapeutics, Inc. announced its financial results for the three and nine months ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (…
Results of Operations and Financial Condition. On August 7, 2025, Black Diamond Therapeutics, Inc. announced its financial results for the three and six months ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exc…
Results of Operations and Financial Condition. On May 12, 2025, Black Diamond Therapeutics, Inc. announced its financial results for the three months ended March 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act…
Entry into a Material Definitive Agreement. On March 18, 2025, Black Diamond Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Servier Pharmaceuticals LLC (“Servier”). Under the terms of the License Agreement, the Company granted to Servier a worldwide license to develop and commercialize BDTX-4933, a small molecule designed by the Company to address unmet medical needs in RAF/RAS-mutant solid tumors. Pursuant to the terms of the License Agreem…
Results of Operations and Financial Condition. On March 6, 2025, Black Diamond Therapeutics, Inc. announced its financial results for the year and three months ended December 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.